NCT06438263已完成1 期
An Open-label, Phase 1, Single Dose, Randomized, Parallel-group Study to Assess the Relative Bioavailability of Rocatinlimab (AMG 451) Autoinjector and Vial in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 231
- 试验地点
- 3
- 主要终点
- AUC From Time Zero to Infinity (AUCinf) of Rocatinlimab
研究概览
简要总结
The main objective of this study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) autoinjector dose compared to vial in healthy participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participant has provided informed consent before initiation of any study-specific activities/procedures.
- •Healthy male or female participants, between 18 and 60 years of age (inclusive)
- •Body mass index between 18 and 32 kg/m2 (inclusive)
排除标准
- •History or evidence, at Screening or Check-in, of clinically significant disorder, condition, or disease not otherwise excluded that, in the opinion of the Investigator (or designee), would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
- •History or evidence of clinically significant arrhythmia at Screening, including any clinically significant findings on the ECG taken at Check-in.
- •A QT interval corrected for heart rate using Fridericia's method (QTcF) > 450 msec in male participants or > 470 msec in female participants or history/evidence of long QT syndrome at Screening or Check-in.
- •Systolic blood pressure ≥ 140 mmHg or ≤ 90 mmHg, or diastolic blood pressure ≥ 90 mmHg or ≤ 50 mmHg, or pulse rate ≥ 100 bpm or ≤ 40 bpm
- •History of hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee). Participants with seasonal allergies will be permitted.
- •Estimated glomerular filtration rate less than 70 mL/min/1.73 m2
- •Alanine aminotransferase or aspartate aminotransferase > 1.5 times the upper limit of normal at Screening or Check-in.
- •Positive hepatitis B or hepatitis C panel (including positive hepatitis B surface antigen [HBsAg] and/or positive hepatitis C antibody) and/or positive human immunodeficiency virus test at Screening. Participants whose results are compatible with prior hepatitis B vaccination (positive hepatitis B surface antibody, negative hepatitis B core antibody, negative HBsAg) or prior infection (positive hepatitis B core antibody, positive hepatitis B surface antibody, negative HBsAg) may be included.
- •Participants who have received live vaccines within 5 weeks prior to Screening, or plan to receive live vaccines within 90 days after administration of an investigational product.
- •Inactive vaccination (e.g., non-live or nonreplicating agent), including coronavirus-2019 (COVID-19) vaccination, is allowed.
- •History of latent tuberculosis or active chronic, recurrent, or acute infection requiring treatment with systemic antibiotics, antiviral, antiparasitic, antiprotozoal, or antifungals which has not completely resolved, or for which therapy has not been completed, within 4 weeks before Screening.
- •Use of any over-the-counter or prescription medications within 30 days or 5 half-lives (whichever is longer) before Check-in, excluding the following:
- •Acetaminophen (paracetamol) (up to 2 g per day) for analgesia will be allowed.
- •Hormonal contraception listed in Appendix 3 will be allowed.
- •Hormone replacement therapy (e.g., estrogen) and hormonal contraceptives will be allowed.
- •All herbal medicines (e.g., St. John's wort), vitamins, and supplements consumed by the participant within the 30 days prior to Check-in, unless deemed acceptable by the Investigator (or designee) and in consultation with the Sponsor.
- •Participant has received a dose of an investigational drug within the past 90 days or 5 half-lives, whichever is longer, prior to Check-in.
- •Have previously completed or withdrawn from this study or any other study investigating rocatinlimab or have previously received rocatinlimab.
研究组 & 干预措施
Treatment A
Experimental
Participants will be randomized to receive a single dose of rocatinlimab vial solution for SC injection.
干预措施: Rocatinlimab (Drug)
Treatment B
Experimental
Participants will be randomized to receive a single dose of rocatinlimab autoinjector for SC injection.
干预措施: Rocatinlimab (Drug)
结局指标
主要结局
AUC From Time Zero to Infinity (AUCinf) of Rocatinlimab
时间窗: Up to approximately 112 days
Maximum Plasma Concentration (Cmax) of Rocatinlimab
时间窗: Up to approximately 112 days
Area Under the Serum Concentration-time Curve (AUC) From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Rocatinlimab
时间窗: Up to approximately 112 days
次要结局
- Number of Participants with Anti-rocatinlimab Antibodies(Up to approximately Day 112)
- Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)(Approximately 20 weeks)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy ParticipantsAtopic DermatitisNCT06268860Amgen240
已完成
1 期
A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese ParticipantsAtopic DermatitisNCT06214481Amgen20
已完成
3 期
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)Atopic DermatitisNCT05704738Amgen532
已完成
3 期
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)Atopic DermatitisNCT05398445Amgen769
已完成
3 期
A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)Atopic DermatitisNCT05633355Amgen187